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Abstract: In pancreatic Panc-1 cancer cells, an increase of oxidative stress enhances the level of
7,8-dihydro-8-oxoguanine (8OG) more in the KRAS promoter region containing G4 motifs than in
non-G4 motif G-rich genomic regions. We found that H2O2 stimulates the recruitment to the KRAS
promoter of poly [ADP-ribose] polymerase 1 (PARP-1), which efficiently binds to local G4 structures.
Upon binding to G4 DNA, PARP-1 undergoes auto PARylation and thus becomes negatively charged.
In our view this should favor the recruitment to the KRAS promoter of MAZ and hnRNP A1,
as these two nuclear factors, because of their isoelectric points >7, are cationic in nature under
physiological conditions. This is indeed supported by pulldown assays which showed that PARP-1,
MAZ, and hnRNP A1 form a multiprotein complex with an oligonucleotide mimicking the KRAS
G4 structure. Our data suggest that an increase of oxidative stress in Panc-1 cells activates a
ROS-G4-PARP-1 axis that stimulates the transcription of KRAS. This mechanism is confirmed by
the finding that when PARP-1 is silenced by siRNA or auto PARylation is inhibited by Veliparib,
the expression of KRAS is downregulated. When Panc-1 cells are treated with H2O2 instead, a strong
up-regulation of KRAS transcription is observed.
Keywords: G4 DNA; KRAS; oxidative stress; 8-oxoguanine; PARP-1; transcription factors;
transcription regulation
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers with a median
survival of about 6–8 months after diagnosis [1]. This poor prognosis is ascribable to its high aggressive
nature and its resistance to conventional chemotherapies. Recent studies have demonstrated that point
mutations in the KRAS proto-oncogene are the initial step of the PDAC carcinogenesis [2]. In the
mutated form, the oncogene reprograms the metabolism of PDAC by increasing the glycolytic flux,
the glutamine and serine metabolism, in order to generate biomass and reducing power necessary for
tumor growth [3–5]. The dependence of the metabolic pathways on specific oncogenes led to the concept
of “oncogene addiction”, according to which cancer cells although depending on a number of genetic
aberrations often develop a dependency on a particular oncogene [6,7]. As PDAC cells are addicted to
mutant KRAS, this oncogene has become the focus of intense investigation [8]. In our laboratory we
discovered that the KRAS promoter contains upstream of the transcription start site (TSS) a G-rich
region adopting a G-quadruplex (or G4) structure recognized by several transcription factors [9–11].
The presence in the KRAS promoter of this unusual DNA conformation has been confirmed by ChIP-seq
analysis carried out on transcriptionally active chromatin [12]. Although some hypotheses on the
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role of G4 DNA in gene regulation have been suggested, the data so far obtained are insufficient to
propose a general mechanism for transcription regulation by G4 DNA [13,14]. In 2012 we discovered
that PARP-1 binds to the KRAS G4 region located upstream of TSS [11]. While PARP-1 was originally
described as a protein involved in DNA repair [15], several studies suggest that it has also a role in
transcription regulation [16–18]. It has been reported that PARP-1 behaves as a modulator of chromatin,
a regulator for DNA-binding transcription factors and DNA methylation [19]. Human PARP-1 is a
113 kDa protein composed by an amino-terminal DNA binding domain comprising two zinc-finger
motifs, a B domain containing a nuclear localization signal and a caspase-3 cleavage site, a central
auto-modification domain allowing protein–protein interactions and a C-terminal domain harboring a
highly conserved sequence that forms the catalytic site [20,21]. PARP-1 binds and cleaves NAD+ to
nicotinamide and ADP-ribose (ADPR), and it couples one or more ADPR units to acceptor proteins,
including itself. These may become mono(ADP-ribosyl)ated or poly(ADP-ribosyl)ated: A modification
called PARylation [20,21]. Most PARP-1 functions are localized in the nucleus, where the protein is
involved in DNA repair, chromatin structure, transcription, translation and oxidative stress [15,19,21].
In the present work we focus on the role of PARP-1 in transcription regulation of KRAS in PDAC cells.
We report that PARP-1 is associated to a G4-motif region of the KRAS promoter, in particular when the
cellular levels of oxidative stress and 8-oxoguanine (8OG) are increased. We also found that PARP-1,
upon binding to the KRAS promoter G4 structures, undergoes auto PARylation. This seems to induce
the recruitment of the transcription factors hnRNP A1 and MAZ and the formation of the transcription
pre-initiation complex. Previous studies from our and other laboratories showed that MAZ and hnRNP
A1 bind to the promoter G4 region of KRAS and activate transcription [22–27]. In summary, in this
study we have identified a ROS-G4-PARP-1 axis that controls the expression of KRAS under conditions
of enhanced oxidative stress.
2. Results and Discussion
2.1. G4 Formation in the KRAS Promoter and Guanine Oxidation
The promoter of the human KRAS proto-oncogene contains, between −270 and −118 (3′→5′,
non-coding strand) from the transcription start site (TSS), three G4 motifs hereafter called G4 32R
(also called G4 near), G4 mid and G4 far (Figure 1) [9,28,29]. Previous studies have demonstrated
that G4 32R and G4 mid form stable G4 structures under physiological conditions, whereas G4 far
forms a G4 which is too weak for determining a thermal stability [28]. In Figure 1 we report typical
CD spectra of G4 32R and G4 mid in 100 mM KCl, at 25 and 95 ◦C. Both exhibit a strong ellipticity
at ~265 nm, in agreement with the formation of parallel G4 structures which have TM’s of 62 and
78 ◦C, respectively. DMS footprinting experiments showed that G4 32R forms a parallel tri-stacked
G4 with a 1/1/12 topology, characterized by two 1-nt loops, a 12-nt loop and a T-bulge in one strand
(Supplementary Information S3) [11]. A recent NMR study confirmed this structure, but showed that
it is in equilibrium with a conformer containing a 11-nt loop, a folded-back guanine and 3-nt cap at
the 3′-end [30]. By contrast, G4 mid comprising seven G-runs of at least three guanines can fold in
different ways. In 100 mM KCl, G4 mid can fold into a quad-stacked G4 involving G-runs 1, 2, 5, and 6,
as proposed in ref. [28]. It embeds, however, two contiguous G4 motifs, each of which is potentially
able to form a tri-stacked G4. We called them G4 mid1 and G4 mid2 (Supplementary Information S4
and Table 1). The CD of G4 mid1 suggests that this sequence folds into a parallel G4. Instead, the CD of
G4 mid2, showing a strong ellipticity at 260 nm and a shoulder at 295 nm, indicates that the sequence
might adopt a mixed parallel/antiparallel G4. These G4 structures show TM’s in 100 mM KCl of 59 ◦C
(G4 mid1) and 67 ◦C (G4 mid2) (Figure 2A, Supplementary Information S5). The presence in vivo of
folded G4 structures in the KRAS promoter has been confirmed by a ChiP-seq analysis carried out on
transcriptionally active chromatin [12].
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Figure 1. KRAS G4-motif sequences located upstream of the transcription start site (TSS). The G4 
motifs are located in the non-coding strand between -118 and -270 from TSS: G4 32R (sequence in red, 
-118/-149); G4-mid (sequence in green, -163/-217; G4-far (sequence in blue, -229-264). G4 32R and G4 
mid form G4 structures with a well-defined melting profile. The CD of these sequences (at 25 and 95 
°C) suggest the formation of parallel G4 structures. The structure of a G-tetrad, where each guanine 













































Figure 1. KRAS G4-motif sequences located upstream of the transcription start site (TSS). The G4 motifs
are located in the non-c ding strand between -118 and -270 from TSS: G4 32R (sequence in red,
-118/-149); G4-mid (sequ nce in green, -163/-217; G4-far (sequence in blue, -229-264). G4 32R and
G4 mid form structures with a well-defined melting profile. The CD of these sequences (at 25 and
95 ◦C) suggest the formation of paral el G4 structures. The structur of a G- etrad, wh re ach guanine
forms 4 hydrogen b nds with neighboring guanines, is s own.
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Figure 2. (A) CD spectra at 25 and 95 ◦C for the G4 mid1 and G4 mid2 sequences; (B) structure of
biotinylated G4 ligand b-6438, which shows much more affinity for G4 DNA than duplex DNA, used
in chro atin pull-do n experi ents. Pull do n-ChIP experi ental sche e. Chro atin frag ents
ith 4 are depicted in black, frag ents ithout 4 in blue; (C) the results of the pull do n-ChIP
experi ent show that 8OG and the G4 motif co-localize in the region of the KRAS promoter containing
G4 32R compared to control regions ctr1 and ctr2, located more than 4500 and 2500 bp away from TSS,
respectively. Error bars from three experiments, Student t-test, (*) = p < 0.05.
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Table 1. DNA sequences used in this work.
Oligonucleotide 5′ → 3′ 8OG
G4 32R AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG
92 AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG (1) (3) 1





b-92 b-TTTTAGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG (1) (2) (3) 1








b-mid1OX b-TTTTCGGGGAGAAGGAGGGGGCCGGGCCGGGC (1) (2) 1











(1) Underlined G = 7,8-dihydro-8-oxoguanine (8OG); (2) b = biotin; (3) 92 and 96 = G4 32R analogues containing 8OG.
It has been found that guanine, in particular in G-rich sequences, is susceptible to oxidation to
7,8-dihydro-8-oxoguanine (8OG), due to its low redox potential [31,32]. Indeed, the amount of 8OG in
the genome of aerobic organisms is considered a biomarker for oxidative stress [33]. We previously have
observed that pancreatic cancer cells (Panc-1, BxPC3, and MiaPaCa-2), due to their higher metabolic
rate, show a higher basal level of 8OG than non-cancer HEK 293 cells [34]. We also discovered by
ChIP experiments that when Panc-1 cells are treated with H2O2, 8OG is about 5-fold more abundant in
the KRAS promoter region containing the G4-motifs than in G-rich non-G4 regions located at least
3000 bp away from TSS [35]. These data suggest that guanines in the G4-motifs are more exposed to
oxidation than other guanines. Saito et al. [36] reported that contiguous guanines are characterized
by a higher rate of oxidation than isolated guanines and that the 5′-G in a G-run shows the lowest
ionization potential. To provide further support that 8OG is more abundant in G4 than non-G4 motifs,
we performed a pull-down/ChIP experiment as outlined in Figure 2B. We synthesized a G4-bait,
namely b-6438, by linking biotin to an anthrathiophenedione molecule binding to G4 much more than
to duplex DNA [37].
We previously demonstrated that this molecule efficiently pulls down G4 strands from nucleic-acid
mixtures [37]. Sheared chromatin obtained from untreated (input Chr) and H2O2-treated (sample Chr)
Panc-1 cells were incubated with b-6438 and pulled down with streptavidin-coated magnetic beads.
The recovered chromatin enriched with G4-containing fragments obtained from the input Chr and
sample Chr were immuno-precipitated with an antibody specific for 8OG, and analyzed by qPCR with
primers specific for the promoter G4 region and control ctr1 and ctr2 regions located in the KRAS gene
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(Figure 2B,C) [35]. The results showed that in sample Chr the KRAS promoter region harboring the
G4 motifs contains, compared to ctr1 or ctr2, 3-fold more 8OG than in input Chr. These data further
support the notion that ROS increase the level of 8OG more in the promoter region harboring the
G4 motifs than in G-rich control regions unable to form G4. This is in keeping with an 8OG-Seq analysis
showing that in the mouse genome, 8OG is 2-fold more abundant in gene promoters than in genic and
intergenic regions [38,39]. In a previous work we asked if 8OG affects the topology and stability of
the G4 formed by G4 32R [35]. In brief, we found that when the oxidative lesion lies in a loop (as in
sequence 96, Table 1), both the topology (1/1/12) and the stability (~62 ◦C) of the resulting G4 did
not appreciably change. By contrast, when 8OG lies in the G-tetrad core (as in sequence 92, Table 1),
the damaged G-run is replaced by the additional G-run present in G4 32R, through an alternative
folding. This is due to the fact that 8OG destabilizes G-tetrad [35] (Supplementary Information S6).
The topology of G4 changed from 1/1/12 into 4/4/6 and the TM decreases by ~10 ◦C [35]. These data show
that the impact of 8OG on G4 depends on the position of the oxidized base within the G4 motif [40,41].
The effect of 8OG in G4 mid1 and G4 mid2 is similar to that observed with G4 32R. If we assume that
G4 mid1 and G4 mid2 form, as observed for G4 32R, a G4 structure containing a 1-nt loop and a bulge
in one strand, 8OG in G4 mid1OX and G4 mid2OX are expected to fall in the G4 core, destabilizing the
structure. Indeed, we found that the TM’s of G4 mid1OX and G4 mid2OX are respectively 3 and 4 ◦C
lower than the wild-type analogues (Table 1, Supplementary Information S5).
2.2. Under Oxidative Stress, PARP-1 Is Recruited to the KRAS Promoter where It Binds to G4 32R and
G4 mid1 and G4 mid2
In the past years, evidence that G4 32R is involved in transcription regulation [9,10] has
been provided. G4 32R is located few helical turns upstream of TSS and is recognized by several
transcription factors including PARP-1, Ku70, MAZ, and hnRNP A1 [11]. PARP-1 plays two important
roles on transcription: It promotes the decondensation of chromatin [42] and it acts as a component
of the transcription pre-initiation complex [43]. Due to its critical role in transcription, we focused
here on PARP-1. By electrophoresis mobility-shift assays (EMSA), we explored the capacity of
recombinant PARP-1 to bind to the G4s formed by G4 32R and G4 mid1, G4 mid2 (the entire G4 mid
sequence showed little binding, not shown) (Figure 3A). The results obtained by incubating the
oligonucleotides 5′-labelled with Cy5.5 (50 nM), mimicking the KRAS G4s, with increasing amounts
of PARP-1 (protein:G4 ratios = 0, 2.2, 4.4, 8.6, 17.2, 34.4), are reported in Figure 3B. The interaction
between PARP-1 and the G4s is rather strong, as a 4.4-fold excess of PARP-1 over G4 is sufficient to
show a retarded band in the gel. In contrast, the three unstructured oligonucleotides (at PARP-1/ODN
of 34.4) did not show any affinity for PARP-1 (negative control). It can be seen that protein:G4 ratios < 4
favor the formation of a 1:1 complex, whereas protein:G4 ratios > 4 favor the formation of a 2:1 complex
(2 PARP-1 per G4). We reported in a plot for each G4, the fraction of bound G4 as a function the PARP-1
concentration (Figure 3C). As the curves showed a sigmoidal shape, they have been best-fitted to the
Hill equation. We obtained the following KD’s values: 0.2 ± 0.03 µM for G4 32R; 0.36 ± 0.02 µM for
G4 mid1; 0.37 ± 0.02 µM for G4 mid2. The three best-fits gave a cooperativity Hill coefficient of n ~ 3.
In a previous study, the KD’s between PARP-1 and c-kit-1 or Htelo G4s, determined by surface plasmon
resonance (SPR), were found to be 65 nM for c-kit-1 and 5.8 µM for Htelo [44].
As PARP-1 contains multiple Trp residues in its DNA-binding domain [44], we followed the
binding of PARP-1 to G4 DNA by measuring the quenching of the Trp fluorescence upon addition
of G4 to a PARP-1 solution. In Figure 3D we report a typical titration obtained by adding increasing
amounts of G4 32R to a PARP-1 solution (60 nM). G4 32R quenched the fluorescence by ~50%,
whereas G4 mid1 and G4 mid2 by ~30%. The percentage of quenching (measured at 345 nm) as
a function of increasing amounts of G4 gave the curves shown in Figure 3E. From these plots we
determined the stoichiometry of the interaction by the “tangent” method. The results pointed to a
stoichiometry of two PARP-1 molecules per G4, in keeping with the results obtained with the c-kit
G4 [44] and the EMSA shown in panel 3B.
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The data have been best-fitted to the Hill equation. Error bars are from two experiments; (D) Typical 
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Figure 3. (A) Sequences of G4 32R, G4 mid1 and G4 mid2; (B) EMSA showing the binding of
recombinant PARP-1 to Cy5.5-labelled G4-mid1, G4 mid2, G4 32R and control oligonucleotides ODN1,
ODN2 and ODN3 (50 nM), with increasing amounts of PARP-1. Reaction was carried out in 20 mM
Tris–HCl pH 8, 30 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 8% glycerol, 1% Phosphatase Inhibitor Cocktail
I (Sigma, Milan, Italy), 5 mM NaF, 1 mM Na3VO4, 2.5 ng/mL poly [dI-dC], 50 mM ZnAc for 30 min
at RT. 50 nM Cy5.5-labelled G4 was incubated with 0, 0.11, 0.22, 0.43, 0.86, and 1.72 µM PARP-1;
(C) Plots reporting the fraction of G4 bound to PARP-1 as a function of the PARP-1 concentration.
The data have been best-fitted to the Hill equation. Error bars are from two experiments; (D) Typical
fluorescence titration of PARP-1 with G4 32R. The titration was carried out in a 500 µL quartz cuvette
containing a solution of PARP-1 (60 nM) in 50 mM Na-cacodylate, pH 7.4, 100 mM KCl, 50 µM ZnAc,
1 mM DTT. G4 32R was added to the PARP-1 solution and th readings were performed 5 min after
incubation. he fluoresc nce spectra were recorded at 20 ◦C between 310 and 500 m, excitation at
295 nm. Titrations were carried out also with G4 mid1 and G4 mid2; (E) Plots reporting the % Trp
quenching induced by increasing amounts of G4 32R, G4 mid1, and G4 mid2. Error bars are from two
experiments; (F) ChIP showing the recruitment of PARP-1 to the G4 promoter region compared to
non-G4 control ctr1 and ctr2 regions, following H2O2 treatment of Panc-1 cells. Error bars are from
three experiments, (*) = p < 0.05.
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Next, we explored by ChIP if PARP-1 is recruited to the G4-region of the KRAS promoter when
the cells are treated with H2O2, i.e., after an increase of oxidative stress (Figure 3F). Panc-1 cells were
treated with two doses of H2O2, 0.5 and 1.0 mM, the chromatin was extracted, sheared and used for
a ChIP assay with an antibody specific for PARP-1. Input Chr (from untreated cells) and recovered
Chr (from H2O2 treated cells), immuno-precipitated with antiPARP-1 Ab, were analyzed by qPCR
with primers for the KRAS promoter G4 region and primers for the ctr1 and crt2 regions. The data
obtained showed that the occupancy of the G4 region by PARP-1 compared to control ctr1 and ctr2
regions increased up to 4-fold as a function of H2O2, i.e., in a dose-response manner (Figure 3F).
We have previously reported that MAZ and hnRNP A1 too are recruited to the KRAS promoter
G4 region rich in 8OG, in response to a H2O2 treatment [35]. Indeed, we found by a ChIP-reChiP
experiment that MAZ and hnRNP A1 localize in the promoter region of KRAS, where the 8OG level is
higher than in the control region [35]. Moreover, by EMSA we found that MAZ and hnRNP A1 bind to
both G4 32R [22,23] and G4 mid sequences (Supplementary Information S7, S8).
2.3. G4 32R Forms A Multi-Protein Complex with PARP-1, MAZ and hnRNP A1
The nuclear factors recruited to the critical KRAS G4-region, located upstream of TSS, following
a treatment with H2O2, are likely to form the transcription pre-initiation complex. To support this
notion, we performed biotin-streptavidin pull-down assays with a Panc-1 nuclear extract and as DNA
baits biotinylated G4 32R and G4 mid, in the wild-type or oxidized form (Figure 4B–D). The G4 baits
mimicking G4 32R are wild-type b-32R and its oxidized forms b-92 and b-96 (Table 1). We prepared
DNA baits also for G4 mid: b-mid, b-mid1 and b-mid2 and oxidized analogues b-midOX, b-mid1OX
and b-mid2OX carrying one or two 8OGs (Table 1). Each G4 bait was incubated with 80 µg of nuclear
extract from Panc-1 cells. The proteins bound to the G4 bait were pulled down with streptavidin-coated
magnetic beads, eluted with Laemmli buffer and analyzed by immunoblotting with antibodies specific
for MAZ, hnRNP A1 and PARP-1. It can be seen that the G4 baits mimicking G4 32R (b-32R, b-92
and b-96), independently from their oxidation state, pulled down all three transcription factors.
This suggests that G4 32R forms a multiprotein complex, which is presumably the transcription
pre-initiation complex. The eluates from the beads incubated with the nuclear extract in the absence of
G4 bait, contained a small amount of proteins due to unspecific interactions between the magnetic
beads coated with streptavidin and the proteins (lane “beads”). By contrast, the eluates from the beads
bound to b-32R, b-92, and b-96 contained a higher amount of the target proteins, due to their specific
binding to the G4 structures. The nuclear factors recognize G4 32R also in the duplex conformation
(obtained by hybridizing the biotinylated G4s with the complementary strand). Figure 4B shows that
MAZ and PARP-1 bind to both wild-type and oxidized G4 32R in duplex conformation.
In agreement with previous studies [22], we found that whereas hnRNP A1 binds only slightly to
the wild-type duplex, it binds clearly to the oxidized duplexes.
We also performed pull-down experiments with wild-type and oxidized b-mid, b-mid1 and
b-mid2 as G4 baits (Table 1) (Figure 4C). These show that the 53-mer oligonucleotide b-mid, forming
a putative quad-stacked G4 with a TM = 78 ◦C, is not bound by the nuclear factors, whereas b-mid1
(TM = 59 ◦C) and b-mid2 (67 ◦C) clearly bind to PARP-1. Instead, the binding of MAZ and hnRNP
A1 to G4 mid1 and G4 mid2 is very weak, as the amounts of protein pulled down is comparable
to those present in the input. PARP-1 binds to G4 mid1 and G4 mid2 also when they include 8OG.
Some binding of MAZ to b-midOX is observed. Furthermore, and expectedly, we found that G4 mid in
duplex conformation interacts with PARP-1 and MAZ but not with hnRNP A1 (Figure 4D). Together,
the pull-down assays show that PARP-1, MAZ and hnRNP A1 form with the critical G4 32R sequence
of KRAS, localized immediately upstream TSS, a transcription pre-initiation complex. G4 mid1 and
G4 mid2 seems to have the function of recruiting PARP-1 in the promoter region, thus acting as a
platform for the assembly of the pre-initiation complex.
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Figure 4. (A) Structure of the DNA baits used in the pull-down experiments. The scheme of the
pull-down experiments is illustrated; (B) Pull-down with wild-type and oxidized G4 32R sequence in
the G4 or duplex conformation. b-32R is wild-type G4 32R, while b-92 bears one 8OG in a G-run, b-96
bears two 8OG bases in the 12-nt loop (see structure in ref [35]) (Table 1). The biotinylated G4 or duplex
baits (80 nM) were incubated with 80 µg of nuclear extract for 30 min at RT. The DNA bait-protein
complexes formed were pulled down with streptavidin magnetic beads. The pulled-down proteins
were recovered and analyzed by Western blot with anti MAZ, anti PARP-1 and anti hnRNP A1 primary
antibodies and a secondary antibody conjugated to horseradish peroxidase; (C,D) Pull-down with
wild-type G4 mid sequences b-mid, b-mid1 and b-mid2 or oxidized b-midox, b-mid1ox and b-mid2ox,
in G4 or duplex conformation. The protocol followed is the same as in (B). We reported below each
Western blot the band/input ratios. The uncertainty of these values from two experiments is about 20%;
(*) = the band/input ratios could not be determined.
2.4. PARP-1 Undergoes Autoparylation upon Binding to the KRAS G4
PARP-1 is a protein that catalyzes poly(ADP-ribosyl)ation (PARylation) of target proteins including
itself (auto PARylation). Free PARP-1 consists of 6 independent domains one connected to the other
by a flexible linker [45]. It has been reported that when the protein binds to DNA with a lesion
t rough its two zinc-finger domains, it undergoes a structural change that starts the synthesis of
ADP-ribose units, by using NAD+ (the coenzyme derived from nicoti amide, NAM) as a source
f P-ribose. PARylatio is a heterogeneous reaction in ter s of length (up to 200 ADP-ribose
units) and branching [46–49]. However, PARP-1 ca also transfer few ADP-ribose unit or even only
o e [mono(ADP-ribosyl)ation] [48]. Both properties and function of ARP-1 have been summarized
in a recent review [21]. In the PARylation process, DNA behaves as a positive allosteric effector,
by upregulating the basal catalytic activity of PARP-1. Considering that PARP-1 associated to the
KRAS promoter binds to G4 DNA, we wondered if the G4 structures actually behave as activators of
PARP-1, as DNA with a nick or an abasic site does. There is one report in the literature addressing
this issue: The autoPARylation of PARP-1 observed when the protein interacts with the ckit-1 and
Htelo quadruplexes [44]. To test if the KRAS G4s activate recombinant PARP-1, we performed in vitro
autoPARylation assays (Figure 5).
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Figure 5. (A) The reaction of PARP-1 autoPARylation. NAM = nicotinamide; (B) AutoPARylation of
recombinant PARP-1 induced by a-DNA (positive control from supplier). When Veliparib, an enzymatic
inhibitor of PARP-1 (indicated with In), was added to the reaction mixture no PARylation was
observed (negative control). The Western blot was performed with anti poly/mono ADP-ribose Ab
and a secondary Ab conjugated to horseradish peroxidase. A embrane replica showing the protein
markers (right) is also reported. PP = PARylated PARP-1; (C–G) AutoPARylation of recombinant
PARP-1 (P) induced by KRAS G4 32R (C), 96 (D) and 92 (E) quadruplexes and G4 mid1 (F) and mid2 (G)
quadruplexes. The mixtures contained 10, 20 and 40 nM of PARP-1 and 10 nM G4.
As positive control we used a PARP-1 activator, a-DNA (a lesioned DNA), supplied with the
“PARP-1 Enzyme Activity Assay” kit (Merck Life Science, Milano, Italy). PARP-1 is a 113 kDa protein,
whereas its autoPARylated form induced by a-DNA has a molecular weight > 245 kDa, suggesting an
extensive auto PARylation synthesis. We then used as DNA activator KRAS G4s, both in the wild-type
or oxidized form. The G4 activators (10 nM) were incubated with increasing amounts of PARP-1 (10, 20
and 40 nM) in a buffer containing NAD+. After incubation, the mixtures were blotted and analyzed
with an anti poly/mono ADP-ribose Ab. The results show that the G4 activators promote to a different
extent auto PARylation of PARP-1. The strongest activator is wild-type G4 32R; its oxidized variants
92 and 96 are weaker effectors. Indeed, auto PARylation induced by 92 and 96 is observed only in
the presence of 40 nM PARP-1, while auto PARylation promoted by 32R is detected at 20 nM PARP-1.
As expected, when Veliparib [50] (Supplementary Information S9), an inhibitor of PARP-1, is added
to the reaction mixture, the auto PARylation is not observed. G4 mid1 and G4 mid2, wild-type and
oxidized, promote autoPARylation of PARP-1 as well, but to a lesser extent than G4 32R. Together,
these data demonstrate that both G4 32R and G4 mid1/G4 mid2, in wild-type and oxidized forms,
activate PARP-1 auto PARylation. Next, we asked if PARylation is also observed within the cell context.
We investigated if the proteins recruited to the KRAS promoter, recognizing the G4 structure of G4 32R,
are PARylated. To address this issue, we followed the scheme outlined in Figure 6 Panc-1 cells were
treated with H2O2 to induce guanine oxidation and stimulate the recruitment of PARP-1, MAZ and
hnRNP A1 to the KRAS promoter. The nuclear extracts were treated with biotinylated b-32R, b-92 and
b-96. The pulled down samples were analyzed by Western blot with anti poly/mono ADP-ribose Ab.
It can be seen that all three G4 baits pulled down PARylated proteins. Compared to untreated cells,
the results show that PARylation increases with the cell exposure to H2O2. We also report in the
figure the membrane replicas showing the molecular weight of the protein markers. The molecular
weight of the markers loaded in the gel show that the PARylation involves a protein of ~115 kDa,
suggesting that this is most likely PARP-1. Note that H2O2 gave in the input (protein extract untreated
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with b-G4) PARylated proteins in the range between ~130–250 kDa, while the PARylated protein
captured by the G4 baits gave only a sharp band, corresponding to a protein of the size of PARP-1.
This suggests that PARP-1 captured by G4 is characterized by a limited auto PARylation, if not a mono
(ADP-ribosyl)ation [48].
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2.5. The Transcription Pre-Initiation Complex Formed at G4 32R Contains Parylated PARP-1
The experiment described above showed that there are proteins bound to G4 32R that are
PARylated. Although we had an indication that the main PARylated protein could be PARP-1,
we wanted to unambiguously confirm it. An insight was obtained by the experiment reported
in Figure 7. Nuclear extract from Panc-1 cells untreated or treated with 0.5 or 1.0 mM H2O2 was
pull-down with anti poly/mono-ADP ribose Ab. The recovered PARylated proteins were separated
by SDS-PAGE and blotted on nitrocellulose. Using specific antibodies we tested for the presence
of PARP-1, MAZ and hnRNP A1 within the PARylated proteins. Only PARP-1 turned out to be
PARylated, while MAZ and hnRNP A1 did not. The PARylation of PARP-1 occurs in a dose-response
manner as, compared to untreated cells, autoPARylation increases with the amount of H2O2 used.
The amount of PARylated PARP-1 in the cells treated with 0.5 and 1.0 mM H2O2 is ~4-fold more
abundant than in the input (see bar plot). We concluded that upon binding to the KRAS G4 motif,
PARP-1 undergoes autoPARylation. According to the data reported in this and previous studies,
we are convinced that PARP-1 plays a key role in the mechanism controlling the expression of KRAS in
pancreatic cancer cells. The crucial experimental observation supporting the mechanism proposed in
Figure 8A is that an increase of intracellular ROS results in the upregulation of KRAS up to 2.5-fold,
following H2O2 treatment. A similar result was obtained also when Panc-1 cells were phototreated
with TMPyP4: A cationic porphyrin producing ROS upon irradiation [34]. As stated before, an increase
of ROS enhances the level of 8OG in the G4-region of KRAS and stimulates the recruitment of PARP-1,
MAZ, and hnRNP A1 to the promoter [35]. Pull-down experiments of chromatin with biotinylated
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G4 ligand b-6438 followed by a ChIP with anti 8OG Ab showed that 8OG and G4 DNA co-localize in
the same promoter region (at ~0.2 kb resolution). If we assume that 8OG is present in the G4 motifs,
because of their high guanine content, the recruitment stimulated by H2O2 increases the occupancy of
the promoter G4 motifs by the transcription factors. This is indeed in keeping with pull-down and
Western blot assays showing that the G4 motifs of the KRAS promoter form together with PARP-1,
MAZ and hnRNP A1 the transcription pre-initiation complex. It is possible that 8OG behaves as an
epigenetic mark for the recruitment to the promoter of the transcription factors [51–53]. We observed
that PARP-1 binds to both G4 32R and G4 mid, either in a wild-type or oxidized form. When PARP-1
binds to G4 32R and G4 mid, it undergoes a structural change that makes the protein catalytically
active, capable of auto PARylation. The autoPARylation process promoted by G4 has been confirmed
in vitro, while cell-based experiments with anti poly/mono-ADP ribose and anti PARP-1 Abs showed
that only few ADP-ribose units are present on PARylated PARP-1. The units of ADP-ribose attached
on the surface of the protein assign a negative charge to PARP-1, which becomes anionic in nature.
By contrast, MAZ and hnRNP A1, having isoelectric points (pI) of 8.1 and 9.2, respectively, are cationic
in nature under physiological conditions. Thus, a possible function of PARP-1 bound to the G4 motifs
is to recruit, through electrostatic interactions, the two transcription factors (Figure 8B). In this way
MAZ and hnRNP A1 spatially accumulate in the promoter region where the transcription pre-initiation
complex will be formed. According to this model, KRAS transcription is expected to be inhibited
if MAZ or hnRNP A1 are suppressed. This has indeed been reported in previous works [22,24,35].
Moreover, given the important role attributed to PARP-1, the suppression or inhibition of its catalytic
activity should strongly inhibit KRAS expression. This central issue will be addressed in the next and
last section.
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Figure 7. Anti-PAR immunoprecipitation assay. (Left) Experimental scheme; (Right) Western blot
showing that among the PARylated proteins present in Panc-1 cells treated with 0.5 and 1 mM H2O2,
there is only PARP-1 and not MAZ and hnRNP A1. The bar plot reports the ratio PARP-1 (pulled
down)/PARP-1 (input) as a function of the H2 concentration. Error bars are from two experiments.
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for 2, 6, and 12 h. The cell lysates were obtained to determine the level of expressed KRAS protein 
respect toβ-actin. Band density was assessed with ImageJ Software. The bar plot, reporting the 
average KRAS/β-actin values from the three treatments, shows that KRAS transcription is stimulated 
by ROS; (B) Proposed mechanism of KRAS activation caused by an increase of oxidative stress. A1 = 
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Figure 8. (A) Western blots of lysates obtained from Panc-1 cells treated with 0, 0.25, and 0.5 mM H2O2
for 2, 6, and 12 h. The cell lysates were obtained to determine the level of expressed KRAS protein
respect to β-actin. Band density was assessed with ImageJ Software. The bar plot, reporting the average
KRAS/β-actin values from the three treatments, shows that KRAS transcription is stimulated by ROS;
(B) Proposed mechanism of KRAS activation caused by an increase of oxidative stress. A1 = hnRNP
A1, pI = isolectric point.
2.6. PARP-1 and G4 Are Essential for KRAS Expression
Besides regulating transcription through the modification of chromatin structure [17], PARP-1
interacts with the promoter of KRAS, thus acting as a classical transcription factor. Previous studies
have reported that PARP-1 is associated with RNA Pol II in open chromatin [54]. We therefore asked
what the impact of PARP-1 is on the KRAS promoter. We treated Panc-1 cells for 24 and 48 h with a
PARP-1 specific siRNA and analyzed by Western blot the expression of PARP-1, KRAS and β-actin.
After 48 h the siRNAs suppressed PARP-1 to ~30% of the control (siRNA ctr) and indirectly KRAS to
~10% of the control (Figure 9B). Such a result clearly shows that the expression of KRAS dramatically
depends on PARP-1. We also asked if G4 DNA might play a central role in the formation of the
transcription pre-initiation complex. We therefore transfected Panc-1 cells with a decoy oligonucleotide
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mimicking the G4 formed by G4 32R and measured by Western blot the level of KRAS protein
(Figure 9C). The Western blot shows that 72 h after transfection with 600 nM G4 32R, the expression
of the KRAS protein is completely suppressed. This result suggests that the exogenous G4 32R
oligonucleotide transfected in the cells sequesters the transcription factors that normally form the
transcription pre-initiation complex at the promoter G4 32R sequence. Finally, according to our model,
transcription activation involves autoPARylation of PARP-1 bound to G4 32R and G4 mid1/G4 mid2 in
order to favor the electrostatic recruitment of cationic MAZ and hnRNP A1 on the promoter. To test if
PARP-1 PARylation is an important step in the mechanism activating KRAS transcription, we used
inhibitors of the poly/mono(ADP-ribosyl)ation catalyzed by PARP-1, Olaparib and Veliparib [50,55].
Panc-1 cells were treated with 30 and 70 µM Olaparib and Veliparib for 48 h and the levels of the KRAS
and β-actin proteins were measured by Western blot. The results reported in Figure 9E,F indicate
that Veliparib decreases the expression of KRAS by ~60% compared to the control (untreated cells).
This behavior is fully consistent with our hypothesis that the autoPARylation of PARP-1 plays a critical
role in activating the expression of the KRAS oncogene under oxidative stress.
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Figure 9. (A,B) Western blot assays showing that 10 and 20 nM PARP1 siRNA suppress PARP-1 and
KRAS as well, in Panc-1 cells, control siRNA does not. The analysis was carried out 24 and 48 h after
siRNA treatment; (C) Western blot showing that Panc-1 cells treated with G4 32R inhibits the expression
of KRAS by acting as a G4 decoy which sequester the transcription factors. As a control an oligo dT
was used; (D) Mechanism of action of G4 32R acting as a G4 decoy; (E,F) Western blot experiment.
Panc-1 cells treated with 30 and 70 µM Veliparib (VEL) and Olaparib (OLA), small-molecules inhibiting
the catalytic activity of PARP-1, result in >50% down-regulation of KRAS protein compared to control
(untreated cells). Bands density were assessed with ImageJ Software. The bar plot reports KRAS/β-actin
ratios. Error bars are from two independent experiments.
3. Materials and Methods
3.1. Oligonucleotides
The non-modified oligonucleotides used in this study have been purchased from Microsynth-AG,
Balgach, Switzerland. 8-oxoG-substituted oligonucleotides were synthesized from 8-oxo-dG CEP from
Berry & Associates in 1-µmol scale on solid support by standard procedure, except using concentrated
ammonia in the presence of 2-mercaptoethanol (0.25 M) in the deprotection step, as described by
Bodepudi et al. [56]. The oligonucleotides were purified by reverse-phase high pressure (or high
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performance) liquid chromatography on a Water system 600, equipped with a C18 column (XBridge
OST C18, 19 × 1000 mm, 5 µm). The composition of the oligonucleotides was verified by Matrix
Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF). Sequences are reported in Table 1.
3.2. Cell Culture
Human pancreatic ductal adenocarcinoma cells (Panc-1), bearing a heterozygous missense
G12D mutation in the KRAS gene, were maintained in exponential growth in Dulbecco’s modified
Eagle’s medium High Glucose (DMEM-High Glucose) containing 100 U/mL penicillin, 100 mg/mL
streptomycin, 20 mM L-glutamine and 10% fetal bovine serum. All reagents were purchased from
EuroClone S.p.A., Pero (Milano), Italy.
3.3. Chromatin Immunoprecipitation and Quantitative PCR
ChIP was carried out by using the ChIP-IT® Express Shearing Kit (Active Motif, Carlsbad,
CA, USA). In brief, 8 × 105 Panc-1 cells were seeded in 6-well plates and after 24 h some plates were
treated with 1 or 0.5 mM H2O2 for 30 min in serum-free DMEM-High Glucose. Then, the cells were
washed with phosphate buffered saline (PBS) and fixed for 10 min in serum-free DMEM-High Glucose
containing 1% formaldehyde. After fixing, the cells were washed with cold PBS and Glycine Stop-Fix
Solution was added to arrest the fixing reaction. The cells were then washed again with cold PBS,
treated with Scraping Solution and centrifuged at 720 g for 10 min at 4 ◦C. The pellet was re-suspended
in ice-cold lysis buffer supplemented with PMSF and PIC (protease inhibitor cocktail) and incubated
for 30 min on ice. The cells were transferred to an ice-cold dounce homogenizer for 10 strokes to
release the nuclei. The homogenate was centrifuged for 10 min at 2400 g at 4 ◦C, to pellet the nuclei.
The nuclei were re-suspended in Shearing Buffer and the chromatin sheared by sonication (10 ×
(30 s pulse on/30 s pulse off)) on Bioruptor Plus (Diagenode, Seraing, Belgium) into DNA fragments
of about 300–400 bp. The sheared chromatin was centrifuged at maximum speed for 15 min, 4 ◦C.
The chromatin concentration was determined with a spectrophotometer by UV absorption at 260
nm. Ten micrograms of chromatin were treated overnight at 4 ◦C with 1 µg PARP-1 specific antibody
(Santa Cruz Biotechnology, Heidelberg, Germany). In addition to the antibody, the mixtures were
added with Protein G Magnetic Beads, ChIP buffer-1 and PIC, following the Active Motif Kit protocol.
After overnight incubation at 4 ◦C, the mixtures were spun and the chromatin bound to the antibody
collected with a magnetic bar. The collected beads were washed once with ChIP buffer-1 and twice
with ChIP buffer-2. The beads were then re-suspended in Elution Buffer AM2 and let to incubate on
shaking for 15 min at room temperature. The beads were treated with Reverse Crosslinking Buffer and
the supernatant with the chromatin was collected. 1 µg of chromatin was used as “input” to assess
G4 enrichment after incubation with Ab-PARP1; in addition to the chromatin, the mixtures were added
with ChIP Buffer-2 and 10 mM NaCl. Both input and immuno-precipitated chromatins were heated at
95 ◦C for 15 min, added with Proteinase K and incubated at 37 ◦C for 1 h. Finally, Proteinase K Stop
Solution was added to halt the reaction. The DNA fragments were amplified by qPCR using primers
specific for genomic KRAS (accession number NG_007524):
G4-plus 5′-GTACGCCCGTCTGAAGAAGA-3′ (nucleotides (nt) 4889–4908, 0.2 µM),
G4-minus 5′-GAGCACACCGATGAGTTCGG-3′ (nt 4958–4977, 0.1 µM),
Ctr1-plus 5′-ACAAAAAGGTGCTGGGTGAGA-3′ (nt 12–32, 0.2 µM),
Ctr1-minus 5′-TCCCCTTCCCGGAGACTTAAT-3′ (nt 248–268, 0.2 µM),
Ctr2-plus 5′-CTCCGACTCTCAGGCTCAAG-3′ (nt 7536–7555, 0.15 µM),
Ctr2-minus 5′-CAGCACTTTGGGAGGCTTAG-3′ (nt 7692–7711, 0.15 µM).
The KRAS G4 region is located upstream TSS in the non-coding strand, ctr1 is about 5 k-bp
upstream TSS while ctr2 is in an intron, about 3 k-bp downstream TSS. The % GC contents of the G4,
ctr1, and ctr2 regions are 65, 44 and 59%, respectively. The lower GC content of ctr1 is only apparent
because it contains three 29-mer sequences with a GC content of 55, 59, and 60%. The G4, ctr1, and ctr2
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sequences are within chromatin fragments of 300–400 bp; the length of the amplified sequences are
91, 256, and 176 bp, respectively. The qPCR reactions were carried out with a CFX-96 real-time PCR
apparatus controlled by Optical System software (version 3.1) (Bio-Rad Laboratories, Segrate (Milano),
Italy) on 1 µL of immuno-precipitated chromatin or input, which were mixed to Sybr Green mix
following manufacturer instructions (Kapa Sybr Fast QPCR Mix, Kapa Biosystems, MA, USA) and
primers. For G4-region amplification cycles were: 3 min at 95 ◦C, 40 cycles 30 s at 95 ◦C and 40 s
at 59 ◦C. For controls amplification cycles were: 3 min at 95 ◦C, 40 cycles 10 s at 95 ◦C and 30 s at
57 ◦C (ctr1) or 61 ◦C (ctr2). All reactions have been validated before amplification for each target and
couple of primers. The Ct-values (number of cycles required for the fluorescent signal to cross the
threshold) given by the instrument (Bio-Rad, CFX96 Real-time PCR detection System) were used to
evaluate the difference between sample and input. The adjusted Ct input was obtained by Ct input –
log2 (input dilution factor). Then ∆Ct = Ct sample − Adjusted Ct input. The % Input for each sample
was calculated as follows: % Input = 100 × 2−∆Ct. The % Input was obtained for the G4 region and also
for the non-G4 regions (ctr1 and ctr2). The enrichment in 8-oxoG or MAZ or hnRNP A1 or OGG1 of
the G4 region respect to the non-G4 regions was determined by the ratio:
[% Input (G4 region)]/[% Input (non-G4 region)]
3.4. Mobility Shift Assays
Recombinant PARP-1 was purchased by Antibodies-online GmbH, Germany and provided as
powder; the lyophilized protein was reconstituted with dH2O following manufacturer instructions.
Recombinant MAZ and hnRNP A1 proteins were obtained as reported in Supplementary
Information S1. Before EMSA, 5′Cy5.5 G4 oligonucleotides (G4 32R, G4 mid1 and G4 mid2) were
allowed to form their structure in 50 mM Tris–HCl, pH 7.4, 100 mM KCl, heated at 95 ◦C for 5 min
and incubated overnight at RT. Cy5.5-oligonucleotides (50 nM) were treated for 30 min at 25 ◦C with
different amounts of PARP-1/hnRNP A1/MAZ, ([protein]/[oligonucleotide] ratios reported in the text)
in 20 mM Tris–HCl pH 8, 30 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 8% glycerol, 1% Phosphatase Inhibitor
Cocktail I (Merck Life Science, Milano, Italy), 5 mM NaF, 1 mM Na3VO4, 2.5 ng/mL poly [dI-dC],
50 µM ZnAc. After incubation, the reaction mixtures were loaded in 5% TB (1×) polyacrylamide gel
and run at 300 V, 50 mA, 30 W for 2 h at 20 ◦C. After running, the gel was analyzed with Odyssey CLx
Imaging System (Li-COR Biotechnology, Bad Homburg, Germany).
3.5. Nuclear Extract and Biotin-Streptavidin Pull Down Assay
To obtain nuclear extracts, 6 plates of 15 cm diameter of Panc-1 cells at a given confluence were
collected and exposed to 0.5 µM ADP-HPD, an inhibitor of PARG enzyme (Merck Life Science, Milano,
Italy) for 1 h. Subsequently, the cells were washed with PBS and treated with 1mM H2O2 in serum
free DMEM-High Glucose for 2, 4, and 8 min. The cells were collected in PBS buffer, centrifuged at
800 g for 10 min at 4 ◦C. Next, the cells were resuspended in hypotonic buffer (10 mM HEPES-KOH,
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT, 5 mM NaF, 1 mM Na3VO4) and kept
in ice for 10 min. The swollen cells were homogenized with a Dounce homogenizer and the nuclei,
pelleted by centrifugation and resuspended in low-salt buffer (20 mM HEPES-KOH, pH 7.9, 25%
glycerol, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT). Release of nuclear
proteins was obtained by the addition of a high-salt buffer (low-salt buffer containing 1.2 M KCl).
Protein concentration was measured according to the Bradford method. Biotinylated 32R, 92, 96, mid1,
mid2, mid, midox mid1ox and mid2ox were folded in 50 mM Tris-HCl, pH 7.4 and 100 mM KCl by
heating the solutions at 95 ◦C for 5 min and successive incubation at RT overnight. The corresponding
duplexes were obtained by annealing (5 min at 95 ◦C and overnight at RT) the G4 oligonucleotides
with the complementary strands in 50 mM Tris–HCl pH 7.4, 100 mM NaCl. 80 µg of Panc-1 nuclear
extract were incubated for 30 min at RT with 80 nM biotinylated 32R, 92, 96, mid1, mid2, mid, midox,
mid1ox and mid2ox in 20 mM Tris–HCl, pH 7.4, 150 mM KCl, 8% glycerol, 1 mM DTT, 0.1 mM
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ZnAc, 5 mM NaF, 1 mM Na3VO4 and 2.5 ng/µL poly[dI-dC]. Then 80 µg of Streptavidin MagneSphere
Paramagnetic Particles (Promega Italia, Milano, Italy) were added and let to incubate for 30 min at RT.
The beads were captured with a magnet and washed two times. The proteins were denatured and
eluted with Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue
and 0.125 M Tris–HCl).
3.6. Western Blots
Protein samples were separated in 10–12% SDS-PAGE and blotted onto nitrocellulose membrane
at 70 V for 2 h. The nitrocellulose membrane was blocked for 1 h with 5% fat dried milk in PBS and 0.1%
Tween (Merck Life Science, Milano, Italy) at room temperature. The primary antibodies used were:
Anti-MAZ (clone 133.7, IgG mouse, Santa Cruz Biotechnology, Dallas, TX, USA), anti-hnRNP A1 (clone
9H10, IgG mouse, Merck Life Science, Milano, Italy), anti-PARP-1 (polyclonal antibody, IgG rabbit, Cell
Signalling Technology, Leiden, The Netherlands), anti-PAR (Poly/Mono-ADP Ribose (E6F6A) Rabbit
mAb #83732, Cell Signalling Technology, Leiden, The Netherlands), anti-β-actin [Anti-Actin (Ab-1)
Mouse mAb (JLA20)], (Merck Life Science, Milano, Italy), anti-KRAS (Mouse monoclonal Anti-KRAS,
clone 3B10 2F2, Merck Life Science, Milano, Italy). The membranes were incubated overnight at
4 ◦C with the primary antibodies, then washed with 0.1% Tween in PBS and incubated for 1 h with
the secondary antibodies conjugated to horseradish peroxidase: Anti-mouse IgG (diluted 1:5000),
anti-rabbit IgG (diluted 1:5000) and anti-mouse IgM (diluted 1:5000) (Merck Life Science, Milano, Italy).
The signal was developed with Super Signal® West PICO, and FEMTO (Thermo Fisher Scientific,
Waltham, MA, USA) and detected with ChemiDOC XRS, Quantity One 4.6.5 software (Bio-Rad
Laboratories, Segrate, (Milano), Italy). Bands quantification was performed with the ImageJ software.
3.7. PAR Immunoprecipitation Assay
Panc-1 cells were seeded onto 15 cm diameter plates. At a confluence of 80%, the cells were treated
with 1 and 0.5 mM H2O2 in serum-free DMEM High Glucose medium for 30 min. Then the nuclear
proteins were extracted and quantified as described in the “Nuclear extract and biotin-streptavidin
pull down assay”. For immunoprecipitation, 1.5 mg of Protein A-Dynabeads (ThermoFisher
Scientific-Invitrogen, Waltham, MA, USA) were incubated with 3 µg of PAR antibody (Poly/Mono-ADP
Ribose (E6F6A) Rabbit mAb #83732, Cell Signalling Technology, Leiden, The Netherlands) and 3 µg of
IgG Rabbit (ThermoFisher Scientific-Invitrogen, Waltham, MA, USA) as negative control in 20 mM
Tris-HCl, pH 7.4, 150 mM KCl, 8% glycerol, 1mM DTT and 0.1 mM ZnAc for 15 min at RT. After one
wash with the same buffer, 80 µg of nuclear extracts were allowed to react with anti-PAR- and IgG
rabbit-derivatized Dynabeads for 30 min at RT. The beads were captured with a magnet and washed
twice with the same buffer. The proteins were denatured and eluted with Laemmli buffer (4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris–HCl).
3.8. PARP-1 AutoPARylation and Inhibition Assays
Oligonucleotides 32R, 92, 96, mid1, mid2, and mid sequences were allowed to fold into
G-quadruplex as reported previously. 0, 10, 20, and 40 nM rPARP-1 (Antibodies-online, Aachen,
Germany) was incubated with 10 nM biotinylated sequences in 50 mM Tris-HCl, pH 7,4, 50 mM
KCl, 2 mM MgCl2, 1 mM DTT, 50 µM ZnAc and 150 µM NAD+ in 15 µL final volume for each
reaction. Samples include both positive (PARP-1 incubated with activating-DNA from “PARP-1
Enzyme Activity Assay”, Merck Life Science, Milano, Italy) and negative control (PARP-1 incubated
with 400 µM Veliparib inhibitor, purchased from Selleckchem, Munich, Germany). Incubation was
carried out for 30 min at RT and stopped with the addition of Laemmli buffer (4% SDS, 20% glycerol,
10% 2-mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris–HCl).
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3.9. Inhibition of KRAS by G4 Decoys, siRNA and Veliparib
To evaluate KRAS expression by Western blot, 5 × 105 cells/well were seeded onto a 6-well plate
and transfected with 600 nM 32R or 600 nM oligodT (control) by jetPEITM. The cells were collected
72 h after transfection in Laemmli Buffer (4% SDS, 20% glycerol, 0.125 M Tris–HCl, pH 7.4) and lysed
by Bioruptor Plus (Diagenode, Seraing, Belgium) (30 s on/30 s off) repeated 20 times. The proteins in
the lysates were determined by Markwell assay [57].
To evaluate the expression level of KRAS following siRNA or PARP-1 inhibitor treatments,
we seeded Panc-1 cells (4 × 105 cells/well) onto 6-well plate. After 24 h cells were exposed to either
PARP-1 siRNA (Santa-Cruz Biotechnology, Heidelberg, Germany) (10 or 20 nM, 24 and 48 h) or
Veliparib/Olaparib (30 or 70 µM, 48 h) (Selleckchem, Munich, Germany) diluted in DMSO. SiRNA were
delivered with INTERFERin siRNA transfection reagent (Polyplus Transfection, Illkirch, France).
After treatment, the cells were washed with PBS and collected in Laemmli Buffer (4% SDS, 20% glycerol,
0.125 M Tris–HCl). Cell lysates were obtained as described above.
3.10. Panc-1 Nuclear Extract
Untreated or treated Panc-1 cells (8 × 105) (treated with the various molecules used in this study)
were seeded onto a 6-well plate. The following day, the cells were treated with 0, 0.25, and 0.5 mM
H2O2 in serum-free DMEM High Glucose for 2, 6, and 12 h. The medium was then removed, the cells
washed with PBS and collected in Laemmli Buffer (4% SDS, 20% glycerol, 0.125 M Tris–HCl, pH 7.4).
The cells were lysed on Bioruptor Plus (Diagenode, Seraing, Belgium), by adopting as lysis protocol,
30 s on/30 s off, repeated 20 times. The lysates were quantified with Markwell assay [57].
3.11. UV-Melting and CD
UV-melting was performed by using Jasco V-750 UV-visible spectrophotometer equipped with
a Peltier temperature control system (ETCS-761) (Jasco Europe, Cremella, Italy). The spectra were
analyzed with Spectra Manager (Jasco Europe, Cremella, Italy). The oligonucleotides (5 µM) were
annealed in 50 mM Na-cacodylate, pH 7.4 and 100 mM KCl, (5 min at 95 ◦C, overnight at RT).
The melting curves were recorded at 295 nm in a 0.5 cm path length quartz cuvette, heating (25–95 ◦C)
at a rate of 0.5 ◦C/min.
Circular Dichroism (CD) spectra were obtained on a JASCO J-600 spectropolarimeter, equipped
with a thermostated cell holder, with 5 µM oligonucleotide solutions in 50 mM Na-cacodylate, pH 7.4,
100 mM KCl. The spectra were recorded in 0.5 cm quartz cuvette at 25 and 95 ◦C and reported as
ellipticity (mdeg) versus wavelength (nm). Each spectrum was smoothed and subtracted to the baseline.
3.12. Fluorescence Experiments
32R, mid1 and mid2 were allowed to fold into quadruplex in 50 mM Na-cacodylate, pH 7.4,
100 mM KCl, (5 min at 95 ◦C, overnight at RT). The Trp fluorescence was titrated by adding to a
60 nM of recombinant PARP-1 solution (500 µL) in 50 mM Na-cacodylate, pH 7.4, 100 mM KCl, 50 µM
ZnAc, 1 mM DTT, increasing amounts of G4 (see plots). A solution (without PARP-1) was used as
blank. The aliquots of G4 were directly added to the PARP-1 solution and reading was performed
5′ after the incubation between PARP-1 and G4s. The fluorescence was measured on a Cary Eclipse
Fluorescence Spectrophotometer (Agilent Technologies Italia, Cernusco sul Naviglio, Italy), equipped
with a thermostated cell holder. The spectra were recorded at 20 ◦C between 310 and 500 nm, excitation
at 295 nm. Each spectrum was smoothed and subtracted to the baseline.
3.13. Biotinylated-Anthrathiophenedione Pull-Down Assay
The pull down of chromatin fragments containing G4 structures with a G4-specific ligand b-6438
is described in Supplementary Information S2.
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4. Conclusions
In this work we have examined the role of PARP-1 in the activation of the transcription of KRAS
in pancreatic cancer cells. The function of this oncogene is essential in PDAC, as it reprograms the
glucose and glutamine metabolism with the aim of fueling an increased anabolic demand, typical of
rapidly dividing cells [4,5]. Since cancer cells are characterized by a high metabolic rate, they produce
higher levels of ROS than normal cells do. So, we asked what the impact of an enhanced level of
ROS is in maintaining the transformed phenotype of PDAC. The starting points of our study are:
(i) ROS increase the level of 8OG in the genome, in particular in the G4 motifs composed by contiguous
runs of guanines; (ii) ROS stimulate the expression of KRAS, the oncogene to which PDAC cells are
addicted [8]. Burrows and co-workers reported that the oxidation of guanine to 8OG in the VEGF
G4 motif located upstream of Rluc reporter gene increases gene expression by 4-fold [51]. If this
may be considered as a general behavior and if it is applicable to the KRAS gene too, our work
describes a possible mechanism through which 8OG in KRAS promoter upregulates gene expression.
We have hypothesized that an increase of intracellular ROS, due to endogenous (metabolism) or
exogenous (oxidants) sources, may oxidize guanine into 8OG in the G4-motif of the KRAS promoter
located upstream of TSS. The oxidized G-rich sequence provides a platform for the assembly of the
transcriptional machinery [35,52,58]. We already have found that the upregulation of KRAS occurring
in the presence of oxidative stress stimulates the expression of Nrf2 [34]: The master regulator of
cellular redox which activates the detoxification program by bringing down the ROS level for optimal
cell proliferation [59,60]. We present experimental evidence that the activation of KRAS occurs through
a mechanism involving the enrichment in 8OG of the promoter region with the G4 motifs recognized by
transcription factors PARP-1, MAZ, and hnRNP A1. The enrichment of 8OG in the KAS G4 32R region
produces an increase in the same region of the occupancy by PARP-1, MAZ, and hnRNP A1. This is in
agreement with two facts: (i) Recombinant PARP-1 binds in vitro to G4 32R and G4 mid1/G4 mid2
sequences, (ii) biotinylated G4 32R in the G4 conformation pulls down a multi-protein complex
containing the three transcription factors. The binding of PARP-1 to the KRAS promoter activates
the catalytic property of this protein, which by utilizing NAD+ undergoes a limited auto PARylation.
This process changes the net charge of the protein, that becomes anionic. It also favours the recruitment
to the promoter of cationic transcription factors necessary for KRAS transcription, like MAZ and
hnRNP A1. Several reports have indeed assigned to PARP-1 a role in the assembly of regulatory
complexes at the promoter of the genes [17,61]. In keeping with our results Chowdhury and co-worker
found that zinc-finger transcription factors, such as PARP-1 and MAZ, are closely associated to the
G4 motifs in the promoter of the human genes [62]. In conclusion, our study shows that the increase
of KRAS transcription observed in the presence of enhanced levels of oxidative stress is mediated
by PARP-1.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/17/
6237/s1. Supplementary S1: Recombinant proteins MAZ and hnRNP A1. Supplementary S2: Pull-down assay
with b-6438. Supplementary S3: Structure of the G4 formed by sequence 32R (G4-near). Supplementary S4:
Putative structures formed G4 mid1 and G4 mid2. Supplementary S5: Melting curves of G4 mid, G4 midox,
G4 mid1, G4 mid1ox, G4 mid2, G4 mid2ox. Supplementary S6: Structure of a G-tetrad with one G replaced by 8OG.
Supplementary S7: EMSA showing the binding of hnRNP A1 to the G4 mid sequences. Supplementary S8: EMSA
showing the binding of MAZ to the G4 mid sequences. Supplementary S9: Structures of PARP-1 inhibitors
Veliparib and Olaparib.
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Abbreviations
KRAS Kirsten ras gene
MAZ MYC associated zinc finger protein
hnRNP A1 Heterogeneous nuclear ribonucleoprotein A1
PARP-1 Poly[ADP-ribose] polymerase 1
PDAC Pancreatic ductal adenocarcinoma
8OG 8-Oxoguanine
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